Tebas P - Search Results

1

Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro.

Wang X, Douglas SD, Lai JP, Tuluc F, Tebas P, Ho WZ. Wang X, et al. Among authors: tebas p. J Neuroimmune Pharmacol. 2007 Mar;2(1):42-8. doi: 10.1007/s11481-006-9059-6. Epub 2007 Jan 12. J Neuroimmune Pharmacol. 2007. PMID: 18040825

2

Bone disease and HIV infection.

Amorosa V, Tebas P. Amorosa V, et al. Among authors: tebas p. Clin Infect Dis. 2006 Jan 1;42(1):108-14. doi: 10.1086/498511. Epub 2005 Nov 30. Clin Infect Dis. 2006. PMID: 16323100 Review.

3

DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations.

Hoffmann C, Minkah N, Leipzig J, Wang G, Arens MQ, Tebas P, Bushman FD. Hoffmann C, et al. Among authors: tebas p. Nucleic Acids Res. 2007;35(13):e91. doi: 10.1093/nar/gkm435. Epub 2007 Jun 18. Nucleic Acids Res. 2007. PMID: 17576693 Free PMC article.

4

Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.

Manak MM, Moshkoff DA, Nguyen LT, Meshki J, Tebas P, Tuluc F, Douglas SD. Manak MM, et al. Among authors: tebas p. AIDS. 2010 Nov 27;24(18):2789-96. doi: 10.1097/QAD.0b013e3283405c33. AIDS. 2010. PMID: 20975512 Free PMC article.

5

A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.

Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H, Gonin R, Korelitz J, Douglas SD. Tebas P, et al. PLoS One. 2011;6(9):e24180. doi: 10.1371/journal.pone.0024180. Epub 2011 Sep 8. PLoS One. 2011. PMID: 21931661 Free PMC article. Clinical Trial.

6

Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant.

Barrett JS, Bajaj G, McGuire J, Wu D, Spitsin S, Moorthy G, Zhao X, Tebas P, Evans DL, Douglas SD. Barrett JS, et al. Among authors: tebas p. Curr HIV Res. 2014;12(2):121-31. doi: 10.2174/1570162x12666140526120831. Curr HIV Res. 2014. PMID: 24862330 Clinical Trial.

7

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.

Tebas P, Spitsin S, Barrett JS, Tuluc F, Elci O, Korelitz JJ, Wagner W, Winters A, Kim D, Catalano R, Evans DL, Douglas SD. Tebas P, et al. AIDS. 2015 May 15;29(8):931-9. doi: 10.1097/QAD.0000000000000638. AIDS. 2015. PMID: 25915168 Free PMC article. Clinical Trial.

8

Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.

Spitsin S, Tebas P, Barrett JS, Pappa V, Kim D, Taylor D, Evans DL, Douglas SD. Spitsin S, et al. Among authors: tebas p. JCI Insight. 2017 Oct 5;2(19):e95893. doi: 10.1172/jci.insight.95893. JCI Insight. 2017. PMID: 28978797 Free PMC article. Clinical Trial.

9

A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia.

Amorosa V, Synnestvedt M, Gross R, Friedman H, MacGregor RR, Gudonis D, Frank I, Tebas P. Amorosa V, et al. Among authors: tebas p. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):557-61. J Acquir Immune Defic Syndr. 2005. PMID: 16044007

10

Management of potential neurocysticercosis in patients with HIV infection.

Prasad S, MacGregor RR, Tebas P, Rodriguez LB, Bustos JA, White AC Jr. Prasad S, et al. Among authors: tebas p. Clin Infect Dis. 2006 Feb 15;42(4):e30-4. doi: 10.1086/499359. Epub 2006 Jan 17. Clin Infect Dis. 2006. PMID: 16421784

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

298 results

Search Page

Filters